Delvys Rodriguez-Abreu

Universidad de Las Palmas de Gran Canaria

Spain

Research Interests

Explore related searches

Professors in Spain Professors in Cancer Biology Cancer Biology professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (18)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (10)

Bartomeu Massuti

Head Department

Istituto Europeo di Oncologia

SPAIN

View details

Ana Arance

University of Barcelona

SPAIN

View details

Rosalyn Juergens

CANADA

View details

Mario Sznol

Professor, Internal Medicine

Yale University Yale Cancer Center

UNITED STATES

View details

Keith Eaton

Fred Hutchinson Cancer Research Center

UNITED STATES

View details

Hans-Georg Kopp

Head of Department

Robert Bosch Center for Tumor Diseases

GERMANY

View details

Hossein Borghaei

Professor and Chief, Thoracic Oncology

Fox Chase Cancer Center

UNITED STATES

View details

Mariano Provencio Pulla

Head of Medical Oncology Department at Puerta de Hierro University Hospital

Hospital Universitario Puerta del Hierro Majadahonda

SPAIN

View details

Joaquim Bosch-Barrera

Professor Associat Doctor

Universitat de Girona

SPAIN

View details

Javier De Castro

HEAD OF LUNG CANCER UNIT

La Paz University Hospital

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Delvys Rodriguez-Abreu

Research Interests

Explore related searches

Contact this professor

Articles (18)

SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Immune checkpoint blockers in solid organ transplant recipients and cancer: the INNOVATED cohort

Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial

Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer

A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy

Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)

Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients

Addressing lung cancer screening eligibility in Spain using 2013 and 2021 US Preventive Service Task Force criteria: cross-sectional study

Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC

Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC

IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer.

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

Pembrolizumab Plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, 189, and 407.

Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial.

Collaborators (10)

Bartomeu Massuti

Ana Arance

Rosalyn Juergens

Mario Sznol

Keith Eaton

Hans-Georg Kopp

Hossein Borghaei

Mariano Provencio Pulla

Joaquim Bosch-Barrera

Javier De Castro

Make your next move.